Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesA cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US
Current Medical Research and Opinion, 06/25/09
Charles MS et al. - Under a range of assumptions and study limitations around cohorts, clinical effects, and treatment patterns, this long-term analysis showed that pioglitazone plus metformin, when compared to rosiglitazone plus metformin, was a dominant treatment strategy within the US payer setting. Results were driven by the combination of modest differences in QALYs and modest savings in total complication costs over 35 years.
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Zoledronic acid: an unending tale for an antiresorptive agent
Expert Opinion in Pharmacotherapy, 12/11/09
Insulin therapy in type 2 diabetes: insulin analogue mix 50, a potential role in reducing postprandial hyperglycaemia and cardiovascular disease
Expert Opinion in Pharmacotherapy, 12/11/09
Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation
Core Evidence, 12/11/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Economic consequences of ACS-related rehospitalizations in the US
Current Medical Research and Opinion, 12/10/09
Out-of-pocket Prices of Opioid Analgesics in the United States, 1999–2004
Pain Medicine, 12/10/09
The Impact of Disposables on Project Economics in a New Antibody Plant
BioPharm, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor